key: cord-0899041-sa57l6sw authors: Esmailian, Gabriel; Kobashigawa, Jon A; Nishihara, Keith; Patel, Jignesh K; Czer, Lawrence; Megna, Dominick; Emerson, Dominic; Ramzy, Danny; Trento, Alfredo; Chikwe, Joanna; Esmailian, Fardad title: Heart Transplantation in the Era of the SARS‐CoV‐2 Pandemic: Is It Safe and Feasible? date: 2020-07-07 journal: Clin Transplant DOI: 10.1111/ctr.14029 sha: b416787234934927f6fe3fe706444f02317996a1 doc_id: 899041 cord_uid: sa57l6sw As the SARS‐CoV‐2 pandemic continues to unfold, the number of heart transplants completed in the United States has been declining steadily. The current case series examines the immediate short‐term outcomes of 7 heart transplant recipients transplanted during the SARS‐CoV‐2 pandemic. We hope to illustrate that with proper preparation, planning, and testing, heart transplantation can be continued during a pandemic. We assessed 7 patients transplanted from March 4, 2020 to April 15, 2020. The following endpoints were noted: in‐hospital survival, in‐hospital freedom from rejection, in‐hospital non‐fatal major cardiac adverse events (NF‐MACE), severe primary graft dysfunction, hospital length of stay, and ICU length of stay. There were no expirations throughout the hospital admission. In addition, there were no patients with NF‐MACE or treated rejection, and 1 patient developed severe primary graft dysfunction. Average length of stay was 17.2 days with a standard deviation of 5.9 days. ICU length of stay was 7.7 days with a standard deviation of 2.3 days. Despite the decreasing trend in completed heart transplants due to SARS‐CoV‐2, heart transplantation appears to be feasible in the immediate short term. Further follow up is needed, however, to assess the impact of SARS‐CoV‐2 on post‐heart transplant outcomes months after transplantation. Heart transplantation continues to be an optimal treatment for select patients with end stage heart failure. However, throughout its 52-year history, heart transplantation has not faced the impact of a pandemic near the scope of SARS-CoV-2. In the wake of the current SARS-CoV-2 pandemic, there has understandably been concern regarding solid organ transplantation given the highly immunosuppressed state of post-transplant recipients 1 . These patients are at increased susceptibility for viral and bacterial infection with possible risk of graft rejection as immunosuppression dosages are slowly lowered to fight the infection 2 . Despite the continuation of transplant surgeries, the impact of SARS-CoV-2 on the transplant community is already apparent. Starting February 23, 2020 and continuing into the middle of April, there was a decline in the number of heart transplant waitlist additions in the United States. From March 15 to April 11, the rate of inactivation exceeded that of additions with an overwhelming majority of inactivation being noted as SARS-CoV-2 precaution 3 . Moreover, between March 8 and May 2, there was a 24.1% decrease in donors recovered and a 23.8% decrease in completed heart transplants when compared to approximately two months prior to the pandemic 3 . As more states maintain efforts to control the spread of the virus, the current downward trend in heart transplants completed will surely continue. To help combat the spread of the virus and limit resource usage, many centers around the nation, including ours, have suspended elective surgeries during the pandemic or "lockdown." However, our center decided to continue with heart transplantation for a select group of high urgency-listed patients given the possible increased waitlist mortality should these surgeries be put on hold. Throughout the ongoing SARS-CoV-2 pandemic, short term outcomes of heart transplant recipients have yet to be assessed at a high-volume transplant center. Thus, the purpose of the current case series was to show that heart transplantation continues to be a feasible and effective therapy for select patients despite the current SARS-CoV-2 pandemic. In total, 7 patients transplanted from California's declaration of a State of Emergency on March 4, 2020 to April 15, 2020 were assessed retrospectively at a single center. Informed consent was obtained, and our institutional review board approved the study. This article is protected by copyright. All rights reserved Demographics were noted and the patients were assessed on the following endpoints: in-hospital survival, inhospital freedom from rejection (acute cellular, antibody mediated, and hyperacute), in-hospital non-fatal major cardiac adverse events (NF-MACE: myocardial infarction, new congestive heart failure, percutaneous coronary intervention, implantable cardioverter defibrillator/pacemaker implant, stroke), severe primary graft dysfunction (PGD), hospital length of stay, and ICU length of stay. Table 1 depicts the full demographics for the 7 patients transplanted after March 4, 2020. Mean recipient age 54.3 years with a standard deviation of 13.9 years. Mean donor age was 36.7 with a standard deviation of 12.9 years. There were 2 female recipients and 5 male recipients. Of the 2 females, both had previous pregnancies. Mean Ischemic time was 171.3 minutes with a standard deviation of 43.6 minutes. 5 patients were listed as status 2 prior to transplant. In addition, 1 patient was status 3 and 1 patient was status 4 prior to transplant. None of the patients had durable mechanical circulatory support (MCS) devices and 5 had temporary MCS devices. Diagnoses prior to heart transplant included 5 patients with dilated cardiomyopathy, 1 patient with ischemic cardiomyopathy, 1 patient with amyloid, and 1 patient with recurrent antibody mediated rejection post-transplant. Lastly, 3 patients received combined heart-kidney transplants, and 1 patient had a redo sternotomy. Table 2 depicts the in-hospital admission endpoints for the same 7 recipients. Of these patients, there were no expirations throughout the hospital admission. In addition, there were no in-hospital NF-MACE events or treated rejection. 1 patient developed severe primary graft dysfunction. Average length of stay was 17.2 days with a standard deviation of 5.9 days. ICU length of stay was 7.7 days with a standard deviation of 2.3 days. Our main objective for the current case series was to illustrate that in the era of SARS-CoV-2, where the number of heart transplants has decreased since mid-March 3 , heart transplantation continues to be a safe and feasible option for select patients. Overall, there were no expirations for the 7 patients transplanted during the SARS-CoV-2 pandemic. No patients experienced in-hospital rejection or NF-MACE events, and length of stay metrics were acceptable. One patient with prior sternotomy had a severe case of PGD secondary to significant amount of blood transfusion perioperatively for severe coagulopathy. He required extra-corporeal membrane oxygenation support for 72 hours. However, he has fully recovered. This article is protected by copyright. All rights reserved Several factors may have contributed to the favorable outcomes shown for these recipients. Our initial planning involved prioritizing transplanting status 1-3 patients due to their urgency and potential high waitlist mortality. After discussions with organ procurement agencies, a decision was made that all the donors were to be tested for SARS-CoV-2. The donors from areas denoted as "hot spots," which had significant increases in SARS-CoV-2 incidence, were not excluded. The organs were then allocated after two negative RT-PCR tests. In addition, all the recipients were required to be tested prior to transplantation with a negative result within the seven days prior to transplantation. In the event there was not enough time from obtaining the results of the test and the scheduled donor operating room time, the organ was not accepted by our center. In addition, all status 1-3 patients were isolated in non-SARS-CoV-2 areas of the hospital. Only the primary care givers, such as the attending and fellow, made daily rounds on the patients. Other health care providers who may have had contact with suspected or confirmed positive SARS-CoV-2 patients in the hospital, such as respiratory therapists and nursing staff, would not be assigned to pre-or post-heart transplant recipients. The entire cardiac surgery intensive care unit and coronary care unit were assigned to non-SARS-CoV-2 patients. Standard immunosuppression regimen was maintained without any changes. This included triple therapy with tacrolimus, mycophenolate mofetil and corticosteroid. Anti-thymocyte globulin induction therapy was used in patients with renal insufficiency and dual organ transplantation such as heart-kidney transplantation. Prior to the pandemic and as part of our standard practice, all of our transplant patients were followed routinely by infectious disease doctors postoperatively. Appropriate changes to antimicrobial medications would be Accepted Article made as necessary. During the pandemic, no changes were made to this routine practice. In addition, no serial SARS-CoV-2 testing was done for recipients post operatively. To further limit possible SARS-CoV-2 exposure, our heart transplant outpatient clinic transitioned to telemedicine video visits for all patients over 1 year out post-transplant. In person visits for new transplant recipients continued for the first 6 months post transplantation. However, video visits were utilized on postoperative months 7, 9, and 11 during the pandemic. As part of routine surveillance for detecting early rejection prior to the pandemic, endomyocardial biopsies were obtained for the first 6 months post transplantation. Gene expression profiling, such as AlloMap, was utilized from the 7 th month post transplantation onward. This pattern of surveillance did not change during the pandemic. Blood draws were done at home for gene expression profiling and adjustment of immunosuppressive medication. Lastly, we eliminated the early coronary angiogram during the pandemic. Although recent pandemics have not reached the magnitude of SARS-CoV-2, there have been studies examining the impact of these pandemics on the organ sharing network and transplantation. In 2010, 5 H1N1influenza positive donors were followed in the United Kingdom 4 . Of the 13 recipients who received organs from these donors, none contracted H1N1 influenza 4 . Another case report highlighted four recipients of organs (3 kidneys and 1 liver) from H1N1 positive donors 5 . All four recipients showed good short-term outcomes post-transplant. However, in contrast to H1N1-influenza, SARS-CoV-2 presents a greater challenge due to its severe respiratory sequalae, high transmission rate, and possible asymptomatic transmission 6 . Although the current study did not accept hearts from SARS-CoV-2 positive donors, similar post-transplant outcomes were found compared to the previous study that examined transplanting recipients with H1N1 positive donors 5 . The current study's primary limitation included a small sample size for the patient population transplanted during the SARS-CoV-2 pandemic. The study also examined the recipients' outcomes solely throughout the inhospital admission. Further long-term monitoring is needed to assess the impact of SARS-CoV-2 months after transplantation. In addition, only heart and combined heart-kidney transplant recipients were examined. Therefore, caution must be taken in extrapolating the data to other solid organ transplantation. This article is protected by copyright. All rights reserved Even in the era of a pandemic such as SARS-CoV-2, with proper preparation, testing, and strategic hospital space planning, heart transplantation appears to be feasible with acceptable short-term outcomes. This pattern of practice should continue to provide this therapeutic option to the patients with high waitlist mortality. Furthermore, more stable patients can potentially get transplanted as more donors are tested despite the continuing current downward trend in heart transplants during the pandemic. Dr. Kobashigawa serves as consultant to CareDx. Dr. Patel receives funding from Alexion Pharmaceuticals and serves as a consultant to Care Dx. The remaining authors have no disclosures to report. Gabriel Esmailian: concept/design and drafting article, Jon Kobashigawa: critical revision and approval of article, Keith Nishihara: data analysis/interpretation and data collection, Jignesh Patel: concept/design, Lawrence Czer: data analysis/interpretation, Dominick Megna: data analysis/interpretation, Dominic Emerson: data analysis/interpretation, Danny Ramzy: data analysis/interpretation, Alfredo Trento: data analysis/interpretation, Joanna Chikwe: data analysis/interpretation, Fardad Esmailian: Concept/design and approval of the article Accepted Article COVID-19: Yet Another Coronavirus Challenge in Transplantation Influenza Virus Infection in Adult Solid Organ Transplant Recipients United Network for Organ Sharing Risk of Transmission of H1N1 Influenza by Solid Organ Transplantation in the United Kingdom Transplantation of solid organs procured from influenza A H1N1 infected donors Presumed Asymptomatic Carrier Transmission of COVID-19 This article is protected by copyright. All rights reserved Accepted Article